SupplementScore.org

Resveratrol and metabolic markers: the 2024–2025 glucose and lipid trial update

6 min read · By the · Updated · How we research
Bottom Line

Resveratrol was oversold a decade ago as a longevity molecule on the strength of mouse and worm data, and the 2024–2025 metabolic trials sharpen rather than overturn that verdict: it moves a couple of specific markers, modestly. For glucose it is real but small — a 2024 meta-analysis of 17 type 2 diabetes trials found a 0.34-percentage-point drop in HbA1c and a 6 mg/dL drop in fasting glucose — and above 300 mg/day it lowers systolic blood pressure by about 7 mmHg over 12-plus weeks, while it does nothing meaningful for cholesterol or triglycerides up to 1,000 mg/day. The ceiling is bioavailability: oral resveratrol is almost completely conjugated on first pass, leaving free levels far below what activates SIRT1 in a dish. It is a credible adjunct at 200–500 mg/day for blood sugar in people already on metformin and for borderline blood pressure, but not for weight loss, lipids, lifespan, or preventing cardiovascular events.

Why metabolic markers became the focus

The decade-long failure of resveratrol to extend lifespan in any controlled mammalian trial pushed the field toward intermediate endpoints. Insulin sensitivity and lipid profiles offered shorter trial timelines, validated biomarkers, and a plausible mechanism via SIRT1 activation and AMPK signalling. The 2014 trial in obese non-diabetic men randomised to 150 mg/day trans-resveratrol or placebo for 30 days found improved homeostatic insulin sensitivity and reduced inflammatory markers, setting the template for the modern wave.1

2024–2025 trials on type 2 diabetes

Effects on lipids: largely absent

Lipid trial results have been less coherent. Earlier individual trials showing lipid effects have generally been small, used non-standardised products, or combined resveratrol with other polyphenols.

Blood pressure: a more reliable signal at higher doses

The effect was largest in trials of 12 weeks or longer, consistent with a slow vascular endothelial mechanism via increased eNOS expression rather than acute vasodilation.

Bioavailability remains the ceiling

Oral resveratrol absorbs well but undergoes near-complete first-pass conjugation, leaving free trans-resveratrol concentrations in the nanomolar range — orders of magnitude below the micromolar concentrations that activate SIRT1 in cell culture. Most of the metabolite exposure (resveratrol glucuronides and sulphates) does have biological activity, but quantifying it has been technically difficult.

Where this leaves the supplement

For a patient with type 2 diabetes already on metformin, adding 200–500 mg/day of a reputable resveratrol product for 12+ weeks may produce a HbA1c reduction roughly half the size of an additional 5 mg empagliflozin, and is unlikely to harm at this dose range. For hypertensive adults with borderline blood pressure, doses above 300 mg/day for at least three months have a real, if modest, vascular effect. For weight loss, lifespan, lipid management, or cardiovascular event prevention, the trial evidence does not support a recommendation. Resveratrol in 2026 is a credible adjunct for two specific endpoints, not the broad-spectrum longevity molecule it was sold as a decade ago.

Sources

  1. Brasnyó P, Molnár GA, Mohás M, et al. "Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients." Br J Nutr, 2011;106(3):383-389. PMID: 21385509. DOI: 10.1017/S0007114511000316